NCT03779503

Brief Summary

The aim of this study was to investigate the short-term clinical performance and subjective acceptance of the two study lenses.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 13, 2018

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 19, 2018

Completed
2 months until next milestone

Study Start

First participant enrolled

February 8, 2019

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 18, 2019

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

October 8, 2020

Completed
Last Updated

October 8, 2020

Status Verified

September 1, 2020

Enrollment Period

6 months

First QC Date

December 13, 2018

Results QC Date

August 25, 2020

Last Update Submit

September 14, 2020

Conditions

Outcome Measures

Primary Outcomes (8)

  • Lens Fit - Horizontal Centration

    Assessment of horizontal centration of lens (extremely nasal, slightly nasal, optimum, slightly temporal, extremely temporal)

    Baseline

  • Lens Fit - Horizontal Centration

    Assessment of horizontal centration of lens (extremely nasal, slightly nasal, optimum, slightly temporal, extremely temporal)

    One Week

  • Lens Fit - Vertical Centration

    Assessment of vertical centration of lens (extremely inferior, slightly inferior, optimum, slightly superior, extremely superior)

    Baseline

  • Lens Fit - Vertical Centration

    Assessment of vertical centration of lens (extremely inferior, slightly inferior, optimum, slightly superior, extremely superior)

    One Week

  • Lens Fit - Corneal Coverage

    Assessment of corneal coverage of lens (extremely inadequate, slightly inadequate, optimum, slightly excessive, extremely excessive)

    Baseline

  • Lens Fit - Corneal Coverage

    Assessment of corneal coverage of lens (extremely inadequate, slightly inadequate, optimum, slightly excessive, extremely excessive)

    One Week

  • Lens Fit - Lens Movement

    Lens movement assessed per corneal coverage (extremely inadequate, slightly inadequate, optimum, slightly excessive, extremely excessive)

    Baseline

  • Lens Fit - Lens Movement

    Lens movement assessed per corneal coverage (extremely inadequate, slightly inadequate, optimum, slightly excessive, extremely excessive)

    One Week

Secondary Outcomes (2)

  • Subjective Score for Vision

    Baseline

  • Subjective Score for Vision

    One week

Study Arms (2)

midafilcon A

ACTIVE COMPARATOR

Subjects will be randomized to wear midafilcon A 1 day for one week of daily wear during the study.

Device: midafilcon A

somofilcon A

ACTIVE COMPARATOR

Subjects will be randomized to wear somofilcon A 1 day for one week of daily wear during the study.

Device: somofilcon A

Interventions

midafilcon A 1 day daily disposable contact lens

midafilcon A

somofilcon A 1 day daily disposable contact lens

somofilcon A

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • They are between 18 and 40 years of age (inclusive).
  • They understand their rights as a research subject and are willing to sign a Statement of Informed Consent.
  • They are willing and able to follow the protocol.
  • They are an existing silicone hydrogel reusable spherical contact lens wearer in both eyes.
  • They have a contact lens spherical prescription between -0.25D and -6.00D (inclusive) based on ocular refraction.
  • They own a wearable pair of spectacles and wear them on the day of the initial visit.
  • At dispensing, they can attain at least 0.20 logMAR distance high contrast visual acuity in each eye with the study lenses within the available power range.
  • They are willing to comply with the wear schedule (at least five days per week and for at least eight hours per day).
  • They agree not to participate in other clinical research for the duration of the study.

You may not qualify if:

  • They have an ocular disorder, which would normally contra-indicate contact lens wear.
  • They have a systemic disorder, which would normally contra-indicate contact lens wear.
  • They are using any topical medication such as eye drops or ointment, or use any rewetting/lubricating drops whilst on this study.
  • They are aphakic.
  • They have had corneal refractive surgery.
  • They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.
  • They are pregnant or breastfeeding.
  • They have any ocular abnormality which would, in the opinion of the investigator, normally contraindicate contact lens wear
  • They have any infectious disease which would, in the opinion of the investigator, contraindicate contact lens wear or pose a risk to study personnel; or they have any immunosuppressive disease (e.g. HIV), or a history of anaphylaxis or severe allergic reaction.
  • They have taken part in any contact lens or care system clinical research within two weeks prior to starting this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CooperVision Inc.

Pleasanton, California, 94588, United States

Location

Results Point of Contact

Title
Jose A. Vega, O.D, MSc., FAAO
Organization
CooperVision. Inc

Study Officials

  • Philip Morgan, PhD MCOptom FAAO FBCLA

    Eurolens Research

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 13, 2018

First Posted

December 19, 2018

Study Start

February 8, 2019

Primary Completion

July 30, 2019

Study Completion

September 18, 2019

Last Updated

October 8, 2020

Results First Posted

October 8, 2020

Record last verified: 2020-09

Locations